Skip to main content
SpringerLink
Log in

Antipsychotika

  • Chapter
Handbuch der Psychopharmakotherapie

Auszug

Die Entwicklung der Antipsychotika in den 50-er Jahren des letzten Jahrhunderts hat die psychiatrische Therapie revolutioniert. Sie bildete die Grundlage für die Entlassung zahlreicher Patienten mit chronischen Psychosen aus psychiatrischen Großkrankenhäusern in die gemeindenahe psychiatrische Versorgung („Deinstitutionalisierung“). In den USA führte dieser Prozess über einen Zeitraum von ca. 30 Jahren zu einer 80%igen Reduktion der Zahl der Patienten, die in psychiatrischen Groß- und Landeskrankenhäusern untergebracht waren, von 559.000 im Jahr 1955 über 338.000 im Jahr 1970 bis zu 107.000 im Jahr 1988.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  • Agid O, Kapur S, Arenovich T, Zipursky RB (2003) Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 60: 1228–1235

    Article  PubMed  CAS  Google Scholar 

  • Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA (1993) Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 329: 162–167

    Article  PubMed  CAS  Google Scholar 

  • Arnt J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18: 63–101

    Article  PubMed  CAS  Google Scholar 

  • Baldessarini RJ, Tarazi FI (2006) Pharmacotherapy of psychosis and mania. In: Brunton LL, Lazo JS, Parker KL (eds) Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 11th edn. McGraw-Hill, New York

    Google Scholar 

  • Benkert O, Hippius H (2007) Kompendium der Psychiatrischen Pharmakotherapie. 6. Aufl., Springer, Berlin-Heldelberg New York

    Google Scholar 

  • Benkert O, Gründer G, Wetzel H (1992) Dopamine autoreceptor agonists in the treatment of schizophrenia and major depression. Pharmacopsychiatry 25: 254–260

    PubMed  CAS  Google Scholar 

  • Breier A (1994) Clozapine and noradrenergic function: support for a novel hypothesis for superior efficacy. J Clin Psychiatry 55 (Suppl B): 122–125

    PubMed  Google Scholar 

  • Burstein ES, Ma J, Wong S et al (2005) Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther 315: 1278–1287.

    Article  PubMed  CAS  Google Scholar 

  • Calabrese JR, Keck PE Jr, Macfadden W et al (2005) A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychistry 162: 1351–1360

    Article  Google Scholar 

  • Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 20: 140–144

    CAS  Google Scholar 

  • Centorrino F, Price BH, Tuttle M, Bahk WM, Hennen J, Albert MJ, Baldessarini RJ (2002) EEG abnormalities during treatment with typical and a typical antipsychotics. Am J Psychiatry 159: 109–115

    Article  PubMed  Google Scholar 

  • Ceulemans DL, Gelders YG, Hoppenbrouwers ML, Reyntjens AJ, Janssen PA (1985) Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology Berl 85: 329–332

    Article  PubMed  CAS  Google Scholar 

  • Chakraborty BS, Hubbard JW, Hawes EM et al (1989) Interconversion between haloperidol and reduced haloperidol in healthy volunteers. Eur J Clin Pharmacol 37: 45–48.

    PubMed  CAS  Google Scholar 

  • Chlodo LA, Bunney BS (1985) Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J Neurosci 5: 2539–2544

    Google Scholar 

  • Chou YH, Halldin C, Farde L (2006) Clozapine binds preferentially to cortical D1-like dopamine receptors in the primate brain: a PET study. Psychopharmacology 185: 29–35

    Article  PubMed  CAS  Google Scholar 

  • Correll CU, Leucht S, Kane JM (2004) Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161: 414–425

    Article  PubMed  Google Scholar 

  • Davis JM, Chen N, Glick ID (2004) A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60: 553–564

    Article  Google Scholar 

  • Elkes J, Elkes C (1954) Effect of chlorpromazine on the behaviour of chronically over-active psychotic patients. Br Med J 2: 560–565

    Article  PubMed  CAS  Google Scholar 

  • Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49: 538–544

    PubMed  CAS  Google Scholar 

  • Farde L, Nyberg S, Oxenstierna G, Nakashima Y, Halldin C, Ericsson B (1995) Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 15: 19s–23s

    PubMed  CAS  Google Scholar 

  • Farver DK (2003) Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opin Drug Saf 2: 21–35

    Article  PubMed  CAS  Google Scholar 

  • Geyer MA, Ellenbroeck B (2003) Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27: 1071–1079

    Article  PubMed  CAS  Google Scholar 

  • Goff DC, Sullivan LM, McEvoy JP et al (2005) A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 80: 45–53

    Article  PubMed  Google Scholar 

  • Gründer G, Yokoi F, Offord SJ et al (1997) Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography. Neuropsychopharmacology 17: 175–185

    Article  PubMed  Google Scholar 

  • Gründer G, Wetzel H, Schlösser R et al (1999) Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol Psychiatry 45: 89–97

    Article  PubMed  Google Scholar 

  • Gründer G, Vernaleken I, Benkert O (2001) Welche Eigenschaften machen ein Neuropleptikum ≫atypisch≪? Nervenarzt 72: 833–843

    Article  PubMed  Google Scholar 

  • Gründer G, Carlsson A, Wong DF (2003) Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 60: 974–977

    Article  PubMed  Google Scholar 

  • Gründer G, Landvogt C, Vernaleken I et al (2006) The striatal and extrastriatal D2/D3 receptor binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 31: 1027–1035

    Article  PubMed  CAS  Google Scholar 

  • Guttmacher MS (1964) Phenothiazine treatment in acute schizophrenia; effectiveness: the National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Arch Gen Psychiatry 10: 246–261

    PubMed  CAS  Google Scholar 

  • Haase HJ (1961) Das therapeutische Achsensyndrome neuroleptischer Medikamente und seine Beziehungen zu extrapyramidaler Symptomatik. Fortschr Neurol Psychiatr 29: 245–268

    PubMed  CAS  Google Scholar 

  • Hiemke C, Dragicevic A, Gründer G, Härtter S, Sachse J, Vernaleken I, Müller MJ (2004) Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 26: 156–160

    Article  PubMed  CAS  Google Scholar 

  • Hiemke C, Baumann P, Laux G, Kuss H-J. (2005) Therapeutisches Drug-Monitoring in der Psychiatrie. Psychopharmakotherapie 12: 166–182

    Google Scholar 

  • Hippius H (1999) A historical perspective of clozapine. J Clin Psychiatry 60(Suppl 12): 22–23

    PubMed  Google Scholar 

  • Hogarty GE, Goldberg SC (1973) Drug and sociotherapy in the after-care of schizophrenic patients. One-year relapse rates. Arch Gen Psychiatry 28: 54–64

    PubMed  CAS  Google Scholar 

  • Howes OD, Wheeler MJ, Meaney AM et al (2005) Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment. J Clin Psychopharmacol 25: 259–261

    Article  PubMed  CAS  Google Scholar 

  • Ichlkawa J, Meltzer HY (1991) Differential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and the nucleus accumbens. J Pharmacol Exp Ther 256: 348–357

    Google Scholar 

  • Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP (1999) Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Gerlatr Soc 47: 716–719

    CAS  Google Scholar 

  • Jones PB, Barnes TR, Davies L et al (2006) Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63: 1079–1087

    Article  PubMed  CAS  Google Scholar 

  • Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789–796

    PubMed  CAS  Google Scholar 

  • Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S (1998) 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155: 921–928

    PubMed  CAS  Google Scholar 

  • Keefe RS, Bilder RM, Davis SM et al: CATIE Investigators; Neurocognitive Working Group (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 64: 633–647

    Article  PubMed  CAS  Google Scholar 

  • Kornhuber J, Schultz A, Wiltfang J et al (1999) Persistence of haloperidol in human brain tissue. Am J Psychiatry 156: 885–890

    PubMed  CAS  Google Scholar 

  • Kroeze WK, Hufeisen SJ, Popadak BA et al (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28: 519–526

    Article  PubMed  CAS  Google Scholar 

  • Lane HY, Chang YC, Liu YC, Chlu CC, Tsai GE (2005) Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 62: 1196–1204

    Article  PubMed  CAS  Google Scholar 

  • Li Z, Huang M, Ichikawa J, Dai J, Meltzer HY (2005) N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology 30: 1986–1995

    Article  PubMed  CAS  Google Scholar 

  • Lieberman JA, Stroup TS, McEvoy JP et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005a) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209–1223

    Article  PubMed  CAS  Google Scholar 

  • Lieberman JA, Tollefson GD, Charles C et al: HGDH Study Group (2005b) Antipsychotic drug effects on brain morphology in first-eplsode psychosis. Arch Gen Psychiatry 62: 361–370

    Article  PubMed  CAS  Google Scholar 

  • McEvoy JP, Meyer JM, Goff DC et al (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80: 19–32

    Article  PubMed  Google Scholar 

  • Meaney AM, Smith S, Howes OD, O’Brien M, Murray RM, O’Keane V (2004) Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 184: 503–508

    Article  PubMed  CAS  Google Scholar 

  • Meltzer HY, Matsubara S, Lee JC (1989) The ratios of serotonin 2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25: 390–392

    PubMed  CAS  Google Scholar 

  • Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003a) Serotonin receptors: their key role in drugs to treat schizophrenia. Progr Neuro-Psychopharmacol Biol Psychiatry 27: 1159–1172

    Article  CAS  Google Scholar 

  • Meltzer HY, Alphs L, Green AI et al.: International Suicide Prevention Trial Study Group (2003b) Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60: 82–91

    Article  PubMed  CAS  Google Scholar 

  • Moghaddam B (1994) Preferential activiation of cortical dopamine neurotransmission by clozapine: functional significance. J Clin Psychiatry 55(Suppl B): 27–29

    PubMed  Google Scholar 

  • Newcomer JW (2007) Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 68(Suppl 1): 20–27

    PubMed  CAS  Google Scholar 

  • Oosthuizen PP, Emsley RA, Maritz JS, Turner JA, Keyter N (2003) Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 64: 1075–1080.

    Article  PubMed  CAS  Google Scholar 

  • Roth BL, Sheffler DJ, Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nature Rev Drug Discov 3: 353–359

    Article  CAS  Google Scholar 

  • Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT (2001) Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 58: 1161–1167

    Article  PubMed  CAS  Google Scholar 

  • Schooler NR, Kane JM (1982) Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39: 486–487

    PubMed  CAS  Google Scholar 

  • Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261(5562): 717–719

    Article  PubMed  CAS  Google Scholar 

  • Seeman P, Schwarz J, Chen JF et al (2006) Psychosis pathways converge via D2High dopamine receptors. Synapse 60: 319–346

    Article  PubMed  CAS  Google Scholar 

  • Shapiro DA, Renock S, Arrington E et al (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28: 1400–1411

    Article  PubMed  CAS  Google Scholar 

  • Stille G, Hipplus H (1971) Kritische Stellungnahme zum Begriff der Neuroleptica (anhand von pharmakologischen und klinischen Befunden mit Clozapin). Pharmacopsychiatr Neuropsychopharmacol 4: 182–191

    CAS  Google Scholar 

  • Stöllberger C, Huber JO, Finsterer J (2005) Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol 20: 243–251

    Article  PubMed  Google Scholar 

  • Stroup TS, Alves WM, Hamer RM, Lieberman JA (2006) Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nature Rev Drug Discov 5: 133–146

    Article  CAS  Google Scholar 

  • Stroup TS, Lieberman JA, McEvoy JP et al; CATIE Investigators (2007) Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 164: 415–427

    Article  PubMed  Google Scholar 

  • van Marum RJ, Wegewijs MA, Loonen AJ, Beers E (2007) Hypothermia following antipsychotic drug use. Eur J Clin Pharmacol 63: 627–631

    Article  PubMed  CAS  Google Scholar 

  • Vernaleken I, Slessmeier T, Buchholz HG et al (2004) High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. Int J Neuropsychopharmacol 7: 421–430

    Article  PubMed  CAS  Google Scholar 

  • Wijkstra J, Lijmer J, Balk F, Geddes J, Nolen WA (2005) Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev 19: CD004044

    Google Scholar 

  • Wolkin A, Barouche F, Wolf AP et al (1989) Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 146: 905–908

    PubMed  CAS  Google Scholar 

  • Zimbroff DL, Kane JM, Tamminga CA et al (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry 154: 782–791

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Gerhard Gründer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Max-Planck-Institut für Psychiatrie, Kraepelinstraße 2-10, 80804, München

    Florian Holsboer

  2. Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum der Rheinisch-Westfälischen Technischen Hochschule Aachen, Pauwelsstraße 30, 52074, Aachen

    Gerhard Gründer

  3. Ehemals: Psychiatrische Klinik und Poliklinik der Johannes-Gutenberg-Universität Mainz, Untere Zahlbacher Straße 8, 55131, Mainz

    Otto Benkert

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Gründer, G. (2008). Antipsychotika. In: Holsboer, F., Gründer, G., Benkert, O. (eds) Handbuch der Psychopharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-68748-1_30

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-68748-1_30

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-20475-6

  • Online ISBN: 978-3-540-68748-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation